President Donald Trump holds his executive order on drug pricing with CMS Administrator Mehmet Oz (L) and HHS Secretary Robert F. Kennedy Jr. (R) (Mark Schiefelbein/AP Images)
May 12, 2025 03:31 PM EDTUpdated 03:46 PM
Pharma
Law

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Zachary Brennan

Senior Editor

The White House’s plan to re­align US drug prices with sim­i­lar high-in­come coun­tries has ig­nit­ed a wave of ques­tions about how or even if drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

A service from the Financial Times